Gate has completed dividend payments for 67 stock and ETF entries by crediting users in Tether (USDT) after deducting a 10% withholding tax. These credits cover 58 different ticker symbols, including well-known companies such as Oracle, Cisco Systems, and American Tower. The dividend payments relate to dates from October 19 to October 23, 2026, and span sectors like technology, financial services, energy, and real estate. This automated process credits 90% of the gross dividend amount directly to users without requiring any action from them.
Gate's recent dividend payments in Tether (USDT) for 67 stock and ETF entries provide context for readers interested in dividend-related market activity. For readers following cryptocurrency trends, here is Pluang's market snapshot as of Oct 26, 2026 17:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 26 rose and 22 fell. Notable movers include FTM (Fantom) at Rp11.382 with a -2.05% change, AVAX (Avalanche) at Rp161.632 with a +1.97% change and a 57% sell order activity, and SAND (The Sandbox) at Rp854 with a -1.81% change and 80% sell order activity.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
